BeOne Medicines Ltd ADR Dossier - Source-backed chat

BeOne Medicines Ltd ADR

ONCNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.66

Intrinsic Value $534.72median of 6 methods · middle span $220-$5,723based on filings through 30 Jun 2026

Market Price $365.94Price as of 30 Sep 2026

UndervaluedIntrinsic value is 46% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $41.4B

Enterprise Value $37.4B

Shares Outstanding 113.1M diluted

Moat Rating Wide

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

BeOne entered the second half of 2026 with strong commercial momentum and improving operating leverage: second-quarter revenue increased 30% year over year to USD 1.705 billion, BRUKINSA revenue increased 31% to approximately USD 1.2 billion, GAAP operating income reached USD 325 million, and free cash flow reached USD 435 million. Management consequently raised FY2026 revenue guidance to USD 6.6-6.8 billion. The August 2026 U.S. approval of a TEVIMBRA-based first-line HER2-positive gastroesophageal adenocarcinoma regimen and the advancement of sonrotoclax, tacabrutideg and multiple solid-tumor programs broaden the opportunity beyond BRUKINSA. A Hold rating balances this execution against substantial dependence on continued BRUKINSA growth, clinical and regulatory uncertainty.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets27 analysts · as of 18 Aug 2026

Low · most bearish analyst$370.00

Mean target$433.02

High · most bullish analyst$528.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 2 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$370.0018%

BRUKINSA growth falls below 20%, FY2026 revenue misses the USD 6.6 billion guidance floor, gross margin retreats materially below the guided high-80% range, or multiple late-stage programs are delayed or produce unfavorable data. Commercial uptake of newer products proves insufficient to offset slower hematology growth.

Base CaseCentral scenario

$433.0257%

Matches the consensus mean

BeOne delivers revenue within its USD 6.6-6.8 billion FY2026 range, BRUKINSA remains the principal growth engine, gross margin stays in the high-80% range, and most announced second-half clinical and regulatory milestones progress without material delay. Recently approved products contribute incrementally but do not immediately remove BRUKINSA concentration.

Bull CaseUpside scenario

$528.0025%

BRUKINSA sustains growth above 25%, FY2026 revenue reaches or exceeds the top of guidance, gross margin remains near 90%, and the company completes its announced BRUKINSA, tacabrutideg and solid-tumor milestones. Successful commercialization of BEQALZI and the newly approved TEVIMBRA combination produces visible diversification beyond BRUKINSA.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong current execution: second-quarter 2026 revenue increased 30% year over year, BRUKINSA revenue increased 31%, and management raised full-year revenue guidance to USD 6.6-6.8 billion.
Operating leverage is becoming visible through a 90% GAAP gross margin, USD 325 million of quarterly GAAP operating income and USD 435 million of quarterly free cash flow.
Growth optionality is broadening through the U.S. approvals of BEQALZI and a TEVIMBRA-based first-line HER2-positive GEA regimen, positive Phase 3 MANGROVE results, late-stage tacabrutideg studies and multiple solid-tumor programs.

Key Investment Risks

BRUKINSA remains the dominant commercial product, making the thesis sensitive to its market-share trajectory, competitive dynamics and continued geographic expansion.
Pipeline value depends on favorable clinical results, timely enrollment, regulatory acceptance and successful commercialization; the company itself cautions that trial results may not support further development or approval.
The broad development portfolio and external collaborations increase execution complexity, while delayed milestones or higher-than-expected investment could reduce anticipated operating leverage.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.